169 related articles for article (PubMed ID: 30068692)
21. Impact of clinical, hormonal, radiological, and immunohistochemical studies on the diagnosis of postmenopausal hyperandrogenism.
Sarfati J; Bachelot A; Coussieu C; Meduri G; Touraine P;
Eur J Endocrinol; 2011 Nov; 165(5):779-88. PubMed ID: 21896622
[TBL] [Abstract][Full Text] [Related]
22. Specificity and predictive value of circulating testosterone assessed by tandem mass spectrometry for the diagnosis of polycystic ovary syndrome by the National Institutes of Health 1990 criteria.
Salameh WA; Redor-Goldman MM; Clarke NJ; Mathur R; Azziz R; Reitz RE
Fertil Steril; 2014 Apr; 101(4):1135-1141.e2. PubMed ID: 24534279
[TBL] [Abstract][Full Text] [Related]
23. Is acne a sign of androgen excess disorder or not?
Uysal G; Sahin Y; Unluhizarci K; Ferahbas A; Uludag SZ; Aygen E; Kelestimur F
Eur J Obstet Gynecol Reprod Biol; 2017 Apr; 211():21-25. PubMed ID: 28178574
[TBL] [Abstract][Full Text] [Related]
24. Causes, Patterns, and Severity of Androgen Excess in 1205 Consecutively Recruited Women.
Elhassan YS; Idkowiak J; Smith K; Asia M; Gleeson H; Webster R; Arlt W; O'Reilly MW
J Clin Endocrinol Metab; 2018 Mar; 103(3):1214-1223. PubMed ID: 29342266
[TBL] [Abstract][Full Text] [Related]
25. Postmenopausal hyperandrogenism.
Yoldemir T
Climacteric; 2022 Apr; 25(2):109-117. PubMed ID: 33988479
[TBL] [Abstract][Full Text] [Related]
26. Measurement of selected androgens using liquid chromatography-tandem mass spectrometry in reproductive-age women with Type 1 diabetes.
Gunness A; Pazderska A; Ahmed M; McGowan A; Phelan N; Boran G; Taylor AE; O'Reilly MW; Arlt W; Moore K; Behan LA; Sherlock M; Gibney J
Hum Reprod; 2018 Sep; 33(9):1727-1734. PubMed ID: 30020477
[TBL] [Abstract][Full Text] [Related]
27. Serum testosterone levels measured by isotope dilution-liquid chromatography-tandem mass spectrometry in postmenopausal women versus those in women who underwent bilateral oophorectomy.
Bui HN; Struys EA; Martens F; de Ronde W; Thienpont LM; Kenemans P; Verhoeven MO; Jakobs C; Dijstelbloem HM; Blankenstein MA
Ann Clin Biochem; 2010 May; 47(Pt 3):248-52. PubMed ID: 20406776
[TBL] [Abstract][Full Text] [Related]
28. Ovarian Hyperandrogenism and Response to Gonadotropin-releasing Hormone Analogues in Primary Severe Insulin Resistance.
Huang-Doran I; Kinzer AB; Jimenez-Linan M; Thackray K; Harris J; Adams CL; de Kerdanet M; Stears A; O'Rahilly S; Savage DB; Gorden P; Brown RJ; Semple RK
J Clin Endocrinol Metab; 2021 Jul; 106(8):2367-2383. PubMed ID: 33901270
[TBL] [Abstract][Full Text] [Related]
29. Establishing the cut off values of androgen markers in the assessment of polycystic ovarian syndrome.
Nadaraja RND; Sthaneshwar P; Razali N
Malays J Pathol; 2018 Apr; 40(1):33-39. PubMed ID: 29704382
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of different diagnostic methods for assessment of hyperandrogenism in young women with hirsutism.
Chanukvadze D; Kristesashvili J
Georgian Med News; 2011 Nov; 11(200):25-9. PubMed ID: 22201076
[TBL] [Abstract][Full Text] [Related]
31. Evidence of biochemical hyperandrogenism in women: the limitations of serum testosterone quantitation.
Bell A; Meek CL; Viljoen A
J Obstet Gynaecol; 2012 May; 32(4):367-71. PubMed ID: 22519483
[TBL] [Abstract][Full Text] [Related]
32. Influence of body mass index on measured and calculated androgen parameters in adult women with Hirsutism and PCOS.
Cupisti S; Dittrich R; Binder H; Kajaia N; Hoffmann I; Maltaris T; Beckmann MW; Mueller A
Exp Clin Endocrinol Diabetes; 2007 Jun; 115(6):380-6. PubMed ID: 17701884
[TBL] [Abstract][Full Text] [Related]
33. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients.
Balen AH; Conway GS; Kaltsas G; Techatrasak K; Manning PJ; West C; Jacobs HS
Hum Reprod; 1995 Aug; 10(8):2107-11. PubMed ID: 8567849
[TBL] [Abstract][Full Text] [Related]
34. Postmenopausal virilization in a woman with gonadotropin dependent ovarian hyperthecosis.
Manieri C; Di Bisceglie C; Fornengo R; Grosso T; Zumpano E; Calvo F; Berardengo E; Volante M; Papotti M
J Endocrinol Invest; 1998 Feb; 21(2):128-32. PubMed ID: 9585388
[TBL] [Abstract][Full Text] [Related]
35. Elevated serum levels of anti-Müllerian hormone can be introduced as a new diagnostic marker for polycystic ovary syndrome.
Sahmay S; Atakul N; Aydogan B; Aydin Y; Imamoglu M; Seyisoglu H
Acta Obstet Gynecol Scand; 2013 Dec; 92(12):1369-74. PubMed ID: 23980726
[TBL] [Abstract][Full Text] [Related]
36. Rosiglitazone as treatment for clomiphene citrate-resistant polycystic ovary syndrome: factors associated with clinical response.
Shokeir T; El-Kannishy G
J Womens Health (Larchmt); 2008 Nov; 17(9):1445-52. PubMed ID: 18973428
[TBL] [Abstract][Full Text] [Related]
37. Plasma selenium levels in Turkish women with polycystic ovary syndrome.
Coskun A; Arikan T; Kilinc M; Arikan DC; Ekerbiçer HÇ
Eur J Obstet Gynecol Reprod Biol; 2013 Jun; 168(2):183-6. PubMed ID: 23490536
[TBL] [Abstract][Full Text] [Related]
38. LC-MS/MS improves screening towards 21-hydroxylase deficiency.
Ambroziak U; Kępczyńska-Nyk A; Kuryłowicz A; Wysłouch-Cieszyńska A; Małunowicz EM; Bartoszewicz Z; Kondracka A; Jaźwiec R; Pawłowska E; Szcześniak M; Dadlez M; Bednarczuk T
Gynecol Endocrinol; 2015 Apr; 31(4):296-300. PubMed ID: 25539143
[TBL] [Abstract][Full Text] [Related]
39. Prostate specific antigen (PSA) in diagnosis of polycystic ovarian syndrome - a new insight.
Rudnicka E; Radowicki S; Suchta K
Gynecol Endocrinol; 2016 Nov; 32(11):931-935. PubMed ID: 27426018
[TBL] [Abstract][Full Text] [Related]
40. [Post-menopausal ovarian hyperthecosis].
Castell AL; Hieronimus S; Chevallier A; Sadoul JL; Galand-Portier MB; Delotte J; Fénichel P
Gynecol Obstet Fertil; 2012 May; 40(5):316-9. PubMed ID: 22336524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
